Announced
Synopsis
Valo Health, a biotechnology company, terminated the $2.8bn deal to go public via a SPAC merger with Khosla Ventures Acquisition, a special purposes acquisition company. "We formed KVSA to merge with companies that are impactful to the world as we recently did with KVSB when we merged with Nextdoor. Valo Health is a strong company and we wish them continued success as they move forward on a very solid plan. We will continue to look for other high-impact targets across a range of industries to deliver maximum shareholder value," Samir Kaul, Khosla Ventures Founding Partner and Managing Director.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.